Quince Therapeutics Stock (NASDAQ:QNCX)


RevenueFinancialsChart

Previous Close

$1.76

52W Range

$0.51 - $2.45

50D Avg

$1.61

200D Avg

$1.03

Market Cap

$74.80M

Avg Vol (3M)

$572.69K

Beta

0.71

Div Yield

-

QNCX Company Profile


Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

32

IPO Date

May 09, 2019

Website

QNCX Performance


QNCX Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-34.62M$-52.02M$-90.32M
Net Income$-31.39M$-51.66M$-89.33M
EBITDA$-34.62M$-50.16M$-89.97M
Basic EPS-$-1.54$-3.01
Diluted EPS-$-1.54$-3.01

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 13Nov 07, 13 | 5:00 PM
Q2 13Aug 06, 13 | 5:00 PM
Q1 13May 09, 13 | 5:00 PM

Peer Comparison


TickerCompany
RVMDRevolution Medicines, Inc.
CNTBConnect Biopharma Holdings Limited
NUVBNuvation Bio Inc.
PMVPPMV Pharmaceuticals, Inc.
ACHLAchilles Therapeutics plc
ANTXAN2 Therapeutics, Inc.
NXTCNextCure, Inc.
MLYSMineralys Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
PEPGPepGen Inc.
THRDThird Harmonic Bio, Inc.
TILInstil Bio, Inc.
PHVSPharvaris N.V.
OVIDOvid Therapeutics Inc.
MOLNMolecular Partners AG